Thor Nagel

Mr. Nagel currently serves as Principal of BVF Partners L.P. Prior to joining BVF in 2023, Mr. Nagel was a Senior Analyst at Monashee Investment Management focused on their public and private biotech portfolio. Prior to Monashee, Mr. Nagel worked at Stifel in biotech equity research, and as a consultant at ClearView Healthcare Partners. He holds a B.A. in Chemical Engineering and a minor in Chemistry from Vanderbilt University and a M.S. from the University of Notre Dame.

Mr. Nagel has been a member of Immunic’s Board since February 2026.